1-6 of 6
Xiaowei Xu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors

Jessica L.F. Teh, Dan A. Erkes, Phil F. Cheng, Manoela Tiago, Nicole A. Wilski, Conroy O. Field, Inna Chervoneva, Mitch P. Levesque, Xiaowei Xu, Reinhard Dummer, Andrew E. Aplin
Journal: Cancer Immunology Research
Cancer Immunol Res (2020) 8 (9): 1114–1121.
https://doi.org/10.1158/2326-6066.CIR-19-0743
Published: 01 September 2020
View article titled, Activation of CD8<sup>+</sup> T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors
Open the PDF for Activation of CD8<sup>+</sup> T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors in another window
Includes: Supplementary data
Journal Articles

Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control

Emilio Sanseviero, Erin M. O’Brien, Jenna R. Karras, Tamer B. Shabaneh, Bulent Arman Aksoy, Wei Xu, Cathy Zheng, Xiangfan Yin, Xiaowei Xu, Giorgos C. Karakousis, Ravi K. Amaravadi, Brian Nam, Mary Jo Turk, Jeff Hammerbacher, Mark P. Rubinstein, Lynn M. Schuchter, Tara C. Mitchell, Qin Liu, Erica L. Stone
Journal: Cancer Immunology Research
Cancer Immunol Res (2019) 7 (8): 1371–1380.
https://doi.org/10.1158/2326-6066.CIR-18-0386
Published: 01 August 2019
View article titled, Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control
Open the PDF for Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control in another window
Includes: Supplementary data
Journal Articles

Abstract PR05: Peripheral blood immune profiling of anti-PD-1 therapy in human melanoma reveals a link between T cell re-invigoration and tumor burden that predicts response

Alexander Huang, Michael A. Postow, Robert J. Orlowski, Rosemarie Mick, Bertram Bengsch, Sasi Manne, Wei Xu, Shannon Harmon, Matthew Adamow, Deborah Kuk, Katherine Panangeas, Cristina Carerra, Phillip Wong, Felix Quagliarello, Kristen E. Pauken, Ramin S. Herati, Suzanne McGettigan, Shawn Kothari, Sangeeth M. George, Brandon Wenz, Kurt D'Andrea, Xiaowei Xu, Ravi K. Amaravadi, Giorgos Karakousis, Lynn M. Schuchter, Katherine L. Nathanson, Jedd D. Wolchok, Tara C. Gangadhar, John Wherry
Journal: Cancer Immunology Research
Cancer Immunol Res (2016) 4 (11_Supplement): PR05.
https://doi.org/10.1158/2326-6066.IMM2016-PR05
Published: 31 October 2016
View article titled, Abstract PR05: Peripheral blood immune profiling of anti-PD-1 therapy in human melanoma reveals a link between T cell re-invigoration and tumor burden that predicts response
Journal Articles

Abstract A056: Mechanisms of tumor response and resistance to radiation and dual checkpoint blockade in mice and patients

Christina Twyman-Saint Victor, Andrew Rech, Amit Maity, Ramesh Rengan, Kristen Pauken, Erietta Stelekati, Joseph Benci, Bihui Xu, Hannah Dada, Pamela Odorizzi, Ramin Herati, Kathleen Mansfield, Dana Patsch, Ravi Amaravadi, Lynn Schuchter, Hemant Ishwaran, Rosemarie Mick, Daniel Pryma, Xiaowei Xu, Michael Feldman, Tara Gangadhar, Stephen Hahn, E. John Wherry, Robert Vonderheide, Andy Minn
Journal: Cancer Immunology Research
Cancer Immunol Res (2016) 4 (1_Supplement): A056.
https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR15-A056
Published: 03 January 2016
View article titled, Abstract A056: Mechanisms of tumor response and resistance to radiation and dual checkpoint blockade in mice and patients
Journal Articles

Abstract A38: Phase I study of combination immunotherapy with agonistic CD40 monoclonal antibody (mAb) CP-870,893 (αCD40) and anti-CTLA-4 antibody tremelimumab (treme) in patients with metastatic melanoma

David L. Bajor, Rosemarie Mick, Matthew J. Riese, Richman P. Lee, Xiaowei Xu, Drew A. Torigian, Erietta Stelekati, Martha Sweeney, Brendan J. Sullivan, Lynn M. Schuchter, Ravi Amaravadi, E John Wherry, Robert H. Vonderheide
Journal: Cancer Immunology Research
Cancer Immunol Res (2015) 3 (10_Supplement): A38.
https://doi.org/10.1158/2326-6074.TUMIMM14-A38
Published: 09 October 2015
View article titled, Abstract A38: Phase I study of combination immunotherapy with agonistic CD40 monoclonal antibody (mAb) CP-870,893 (αCD40) and anti-CTLA-4 antibody tremelimumab (treme) in patients with metastatic melanoma
Journal Articles

Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma

David L. Bajor, Xiaowei Xu, Drew A. Torigian, Rosemarie Mick, Laura R. Garcia, Lee P. Richman, Cindy Desmarais, Katherine L. Nathanson, Lynn M. Schuchter, Michael Kalos, Robert H. Vonderheide
Journal: Cancer Immunology Research
Cancer Immunol Res (2014) 2 (11): 1051–1058.
https://doi.org/10.1158/2326-6066.CIR-14-0154
Published: 02 November 2014
View article titled, Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma
Open the PDF for Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma in another window